Point72 Europe’s Maravai LifeSciences MRVI Stock Holding History

Point72 Europe’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$2.11K	Buy	+735	New	+$1.88K	﹤0.01%	659
2024 Q3	–	Sell	-2,468,465	Closed	-$17.7M	–	159
2024 Q2	$17.7M	Buy	2,468,465 +268,122	+12%	+$2.31M	1.46%	15
2024 Q1	$19.1M	Sell	2,200,343 -404,144	-16%	-$2.73M	1.7%	17
2023 Q4	$17.1M	Buy	+2,604,487	New	+$16.8M	2.14%	13
2021 Q1	–	Sell	-30,000	Closed	-$842K	–	36
2020 Q4	$842K	Buy	+30,000	New	+$835K	0.51%	26

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Point72 Europe's MRVI Position: Q3 2025 in Review

Point72 Europe opened a new position in Maravai LifeSciences (MRVI) in Q3 2025: 735 shares worth $2.11K. The stake represents ﹤0.01% of the portfolio and ranks #659 among its holdings. This is a return to the name: Point72 Europe previously reported a position in MRVI as recently as Q2 2024.

Point72 Europe first reported a position in MRVI in Q4 2020 and has held it in 5 quarters since. The position peaked at $19.1M in Q1 2024. 160 funds tracked by Wall St. Rank hold MRVI as of Q3 2025.

Point72 Europe held 735 shares of Maravai LifeSciences worth $2.11K as of Q3 2025.
Maravai LifeSciences was a new Point72 Europe position in Q3 2025.
Maravai LifeSciences made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #659 holding.
Point72 Europe first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 5 quarters since.
Point72 Europe's Maravai LifeSciences position peaked at $19.1M in Q1 2024.
160 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.